Unlocking the Future of Cancer Treatment: Jounce Therapeutics to Showcase Groundbreaking Research at SITC 37th Annual Meeting and ESMO-IO Conference
Jounce Therapeutics Highlights Exciting Research at SITC and ESMO-IO Conferences Exciting Advancements in Cancer Immunotherapy Cambridge, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) – Jounce Therapeutics, Inc. (NASDAQ: JNCE) is set to showcase groundbreaking research at two prestigious conferences, the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society for Medical Oncology’s…